Evidence map›Paper›PMID 41356713›Full record

ArticleRSC advances2025

From chemistry to targeted cancer therapy: potent benzimidazole-1,2,3-triazole hybrid-loaded nanogels against breast and colorectal malignancies.

Azizah M Malebari, Mohamed A M Ali, Arafa Musa, Magdi E A Zaki, Sobhi M Gomha, Moataz A Soliman, Mohamed A Abdelgawad, Della Grace Thomas Parambi, Mohamed R Aouad, Hamada S Abulkhair and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Azizah M MalebariDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, King Abdulaziz University Alsulaymanyah Jeddah 21589 Saudi Arabia.
Mohamed A M AliDepartment of Biology, College of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU) Riyadh 11623 Saudi Arabia.ORCID https://orcid.org/0000-0001-8217-0262
Arafa MusaDepartment of Pharmacognosy, College of Pharmacy, Jouf University Sakaka Aljouf 72388 Saudi Arabia akmusa@ju.edu.sa.ORCID https://orcid.org/0000-0003-0979-556X
Magdi E A ZakiDepartment of Chemistry, Faculty of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU) Riyadh 11623 Saudi Arabia.
Sobhi M GomhaChemistry, Faculty of Science, Islamic University of Madinah Madinah 42351 Saudi Arabia.ORCID https://orcid.org/0000-0002-7739-2837
Moataz A SolimanDeanship of Preparatory Year, Prince Sattam Bin Abdulaziz University Al-Kharj 16273 Saudi Arabia.
Mohamed A AbdelgawadDepartment of Pharmaceutical Chemistry, College of Pharmacy, Jouf University Sakaka Aljouf 72388 Saudi Arabia.
Della Grace Thomas ParambiDepartment of Pharmaceutical Chemistry, College of Pharmacy, Jouf University Sakaka Aljouf 72388 Saudi Arabia.
Mohamed R AouadDepartment of Chemistry, Faculty of Sciences, Taibah University Al-Madinah Al-Munawarah 30002 Saudi Arabia.
Hamada S AbulkhairPharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Al-Azhar University Nasr City 11884 Cairo Egypt heahmad@azhar.edu.eg.ORCID https://orcid.org/0000-0001-6479-4573
Hany E A AhmedPharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Al-Azhar University Nasr City 11884 Cairo Egypt heahmad@azhar.edu.eg.ORCID https://orcid.org/0000-0001-8898-8452

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The therapeutic limitations of conventional anticancer agents, particularly in treating mucosal and epithelial malignancies such as breast and colorectal cancers, necessitate the development of advanced drug delivery systems. This study explores the integration of benzimidazole-1,2,3-triazole hybrids into chitosan/polyvinyl pyrrolidone nanogels to enhance pharmacological performance and target specificity. Comprehensive physicochemical characterization confirmed successful encapsulation and favorable nanogel properties, including controlled particle size, stability, and morphology. Among the tested formulations, the 12ng nanogel demonstrated superior cytotoxicity against the epithelial cancer cells, MDA-MB-231 (IC

Identifiers

PMID41356713
PMCPMC12679356

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.